Please note, this OEL/ADE monograph also applies to methotrexate disodium salt (CAS RN 7413-34-5), methotrexate sodium (CAS RN 15475-56-6), and Methotrexate monohydrate (CAS RN 6745-93-3). Methotrexate is indicated for the treatment of acute lymphoid leukemia, breast cancer, head and neck cancer, juvenile arthritis, lung cancer, lymphoma, bone cancer, psoriasis, and rheumatoid arthritis. Methotrexate is an antimetabolite that interferes with DNA synthesis, repair, and cellular replication by inhibiting dihydrofolate reductase. Tissues with high rates of cellular proliferation such as neoplasms, bone marrow, fetal cells, buccal and intestinal mucosa, and cells of the urinary bladder are generally more sensitive to the effects of methotrexate than most normal tissues.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Methotrexate, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.